Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COURSE A1 + vin appears to be a combination regimen or protocol rather than a single, well-defined pharmaceutical product. The name suggests it may refer to a specific treatment course (possibly in veterinary or investigational medicine) that includes "vin," which could plausibly refer to "vincristine"—a well-known chemotherapeutic agent used in both human and veterinary oncology. However, there is no direct evidence from the provided sources confirming the exact composition or context of "COURSE A1." Vincristine is a vinca alkaloid that inhibits microtubule formation in mitotic spindle, arresting cell division at metaphase and leading to apoptosis of rapidly dividing cells[3]. Without further information on what constitutes "COURSE A1," the full mechanism and intent of this combination cannot be definitively described.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on COURSE A1 + vin.